HPV Vaccine Blocks Cancer-Causing Strains, Experts Confirm Strong Protection
Otamere Gladness 
ABUJA, Nigeria – Health experts reaffirm that the HPV vaccine delivers near-complete protection against high-risk strains responsible for most cervical cancers, strengthening calls for early vaccination.
Public health authorities state that the vaccine targets HPV types 16 and 18—the leading causes of cervical cancer globally—and remains safe and effective when administered before exposure. “The vaccine protects against high-risk HPV 16 and 18 and prevents HPV infection and cervical cancer,” a statement says.
Clinical evidence shows near-total prevention of persistent infection from these strains among vaccinated individuals, particularly when immunisation occurs before sexual debut. As a result, health agencies recommend routine vaccination for preteens, ideally at ages 11 or 12.
Countries with high coverage already report sharp declines in HPV infections and precancerous lesions, signalling future reductions in cancer incidence. Experts say early uptake maximises population-level protection and reduces long-term healthcare costs.
“Vaccination before exposure is the critical window,” a public health specialist note. “It delivers durable protection and shifts the burden away from treatment to prevention.”
Health advocates urge parents and guardians to follow national immunisation schedules and counter misinformation with evidence-based guidance. They also stress the importance of screening alongside vaccination for comprehensive cervical cancer control.
About the Author
Korede Abdullah 
Oluwafunbi Bello 
Edino Chubiyo Cornelius